Diagnosis and management of maturity onset diabetes of the young (MODY)

BMJ (Online)

Volumn 343, Issue 7828, 2011, Pages

  Thanabalasingham, Gaya ^a,b   Owen, Katharine R ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; METFORMIN; NATEGLINIDE; SULFONYLUREA DERIVATIVE;

CLINICAL FEATURE; DELAYED DIAGNOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAMILY HISTORY; FETUS MONITORING; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; GENETIC SCREENING; GEOGRAPHIC DISTRIBUTION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LOW DRUG DOSE; MACROSOMIA; MATURITY ONSET DIABETES MELLITUS; MATURITY ONSET DIABETES MELLITUS OF THE YOUNG; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT REFERRAL; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; REVIEW;

AGE OF ONSET; CHILD; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC TESTING; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84858996746     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d6044     Document Type: Review

References (29)

1. Ledermann HM. Is maturity onset diabetes at young age (MODY) more common in Europe than previously assumed [letter] [see comments]? Lancet 1995;345:648.
2. Shepherd M, Sparkes AC, Hattersley AT. Genetic testing in maturity onset diabetes of the young (MODY); a new challenge for the diabetic clinic. Pract Diabetes 2001;18:16-21.
3. Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med 1974;43:339-57.
4. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010;53:2504-8.
5. Stride A, Vaxillaire M, Tuomi T, Barbetti F, Njolstad PR, Hansen T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 2002;45:427-35. (Pubitemid 34267366)
6. Martin D, Bellanne-Chantelot C, Deschamps I, Froguel P, Robert JJ, Velho G. Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2). Diabetes Care 2008;31:1321-3.
7. Steele A, Shields BM, Shepherd M, Ellard S, Colclough K, Hattersley AT. Microvascular complication risk in patients with 50 years of moderte hyperglycaemia: are target ranges for glycaemic control appropriate? Diabet Med 2011;28:28.
8. Velho G, Blanche H, Vaxillaire M, Bellanne-Chantelot C, Pardini VC, Timsit J, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997;40:217-24. (Pubitemid 27060296)
9. Schober E, Rami B, Grabert M, Thon A, Kapellen T, Reinehr T, et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 2009;26:466-73.
10. Ellard S, Bellanne-Chantelot C, Hattersley AT. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008;51:546-53.
11. Bellanne-Chantelot C, Levy DJ, Carette C, Saint-Martin C, Riveline JP, Larger E, et al. Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. J Clin Endocrinol Metab 2011;96:E1346-E1351.
12. Vaxillaire M, Pueyo ME, Clement K, Fiet J, Timsit J, Philippe J, et al. Insulin secretion and insulin sensitivity in diabetic and non-diabetic subjects with hepatic nuclear factor-1 alpha (maturity-onset diabetes of the young-3) mutations. Eur J Endocrinol 1999;141:609-18. (Pubitemid 30064761)
13. Tripathy D, Carlsson AL, Lehto M, Isomaa B, Tuomi T, Groop L. Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state. Diabetologia 2000;43:1476-83. (Pubitemid 32737205)
14. Thanabalasingham G, Pal A, Farmer AJ, Ellard S, McCarthy MI, Owen KR. Extending criteria for genetic testing increases diagnosis of maturity-onset diabetes of the young Diabetologia 2010;53:S63.
15. Besser RE, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, et al. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-α/hepatocyte nuclear factor 4-α maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011;34:286-91.
16. McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med 2011;28:1028-33.
17. Owen KR, Shepherd M, Stride A, Ellard S, Hattersley AT. Heterogeneity in young adult onset diabetes: aetiology alters clinical characteristics. Diabet Med 2002;19:758-61. (Pubitemid 35013855)
18. Gill-Carey OJ, Shields B, Colclough K, Ellard S, Hattersley AT. Finding a glucokinase mutation alters treatment [abstract]. Diabet Med 2007;24(suppl 1):A6-A20.
19. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue KC. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2009;10(suppl 12):33-42.
20. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003;362:1275-81. (Pubitemid 37324255)
21. Pearson ER, Pruhova S, Tack CJ, Johansen A, Castleden HA, Lumb PJ, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia 2005;48:878-85. (Pubitemid 40767980)
22. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009;26:437-41.
23. Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care 2006;29:189-94. (Pubitemid 44121080)
24. Feigerlova E, Pruhova S, Dittertova L, Lebl J, Pinterova D, Kolostova K, et al. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur J Pediatr 2006;165:446-52. (Pubitemid 43800524)
25. Lorini R, Klersy C, d'Annunzio G, Massa O, Minuto N, Iafusco D, et al. Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. Diabetes Care 2009;32:1864-6.
26. Shield JP. Neonatal diabetes: how research unravelling the genetic puzzle has both widened our understanding of pancreatic development whilst improving children's quality of life. Horm Res 2007;67:77-83. (Pubitemid 46333775)
27. Owen KR, Thanabalasingham G, James TJ, Karpe F, Farmer AJ, McCarthy MI, et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 2010;33:1919-24.
28. Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gasperikova D, et al. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 2011; published online 4 August.
29. McDonald TJ, Shields BM, Lawry J, Owen KR, Gloyn AL, Ellard S, et al. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 2011;34:1860-2.